The estimated Net Worth of David Ross Parkinson is at least $1.29 Million dollars as of 14 December 2023. Dr Parkinson owns over 9,223 units of Essa Pharma Inc stock worth over $463,666 and over the last 7 years he sold EPIX stock worth over $0. In addition, he makes $829,556 as Pres and CEO & Director at Essa Pharma Inc.
Dr has made over 3 trades of the Essa Pharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 9,223 units of EPIX stock worth $21,213 on 14 December 2023.
The largest trade he's ever made was buying 24,434 units of Essa Pharma Inc stock on 22 December 2022 worth over $59,130. On average, Dr trades about 2,141 units every 30 days since 2017. As of 14 December 2023 he still owns at least 65,675 units of Essa Pharma Inc stock.
You can see the complete history of Dr Parkinson stock trades at the bottom of the page.
Dr. David Ross Parkinson M.D. is the Pres, CEO & Director at Essa Pharma Inc.
As the Pres and CEO & Director of Essa Pharma Inc, the total compensation of Dr D at Essa Pharma Inc is $829,556. There are no executives at Essa Pharma Inc getting paid more.
Dr D is 71, he's been the Pres and CEO & Director of Essa Pharma Inc since . There are no older and 2 younger executives at Essa Pharma Inc.
David's mailing address filed with the SEC is C/O ESSA PHARMA INC., 999 WEST BROADWAY, SUITE 720, VANCOUVER, A1, V5Z 1K5.
Over the last 4 years, insiders at Essa Pharma Inc have traded over $924,311 worth of Essa Pharma Inc stock and bought 3,342,445 units worth $15,321,880 . The most active insiders traders include Growth N Vbb Biotech Ag Bio..., Franklin M Berger, and Marella Thorell. On average, Essa Pharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,108,300. The most recent stock trade was executed by Peter Virsik on 9 September 2024, trading 694 units of EPIX stock currently worth $4,164.
as a clinical-stage pharmaceutical company founded on cutting-edge research, essa is focused on developing novel therapeutics for cancer patients. essa embraces innovation not only in our products but also in our approach. we're firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.
Essa Pharma Inc executives and other stock owners filed with the SEC include: